Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

Presentation ACC 2025

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Presenter: Isabelle Mahé

March 29, 2025

Presentation ESC 2024

OCEANIC-AF: Asundexian vs. Apixaban in Patients with Atrial Fibrillation

Presenter: Manesh R. Patel

September 01, 2024

Presentation TCT 2019

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Presenter: Amit Vora

September 28, 2019

Presentation

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Presenter: Paul Dorian

February 20, 2014

Presentation

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Presenter: Stefan H. Hohnloser

August 01, 2013

Presentation

Bleeding with Aspirin vs. Apixaban in Patients with A-fib Unsuitable for Warfarin: The AVERROES Trial

Presenter: Greg C. Flaker

October 09, 2012

Presentation

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Presenter: S. Lee

July 11, 2012

Presentation

Apixaban vs. Aspirin in Patients with A-fib and Previous Stroke or TIA

Presenter: Hans-Christoph Diener

March 08, 2012

Advertisement

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

OCEANIC-AF: Asundexian vs. Apixaban in Patients with Atrial Fibrillation

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Bleeding with Aspirin vs. Apixaban in Patients with A-fib Unsuitable for Warfarin: The AVERROES Trial

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Apixaban vs. Aspirin in Patients with A-fib and Previous Stroke or TIA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content